A detailed history of Brinker Capital Investments, LLC transactions in Axsome Therapeutics, Inc. stock. As of the latest transaction made, Brinker Capital Investments, LLC holds 2,189 shares of AXSM stock, worth $305,781. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,189
Previous 2,136 2.48%
Holding current value
$305,781
Previous $222,000 19.37%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 12, 2025

BUY
$100.39 - $129.29 $5,320 - $6,852
53 Added 2.48%
2,189 $265,000
Q2 2025

Aug 14, 2025

SELL
$95.65 - $116.49 $12,434 - $15,143
-130 Reduced 5.74%
2,136 $222,000
Q1 2025

Jul 31, 2025

SELL
$80.05 - $137.75 $38,824 - $66,808
-485 Reduced 17.63%
2,266 $264,000
Q3 2024

Jul 31, 2025

SELL
$78.93 - $95.84 $4,183 - $5,079
-53 Reduced 1.89%
2,751 $247,000
Q2 2024

Jul 31, 2025

SELL
$65.72 - $80.5 $11,763 - $14,409
-179 Reduced 6.0%
2,804 $225,000
Q1 2024

Jul 31, 2025

BUY
$69.39 - $97.64 $4,163 - $5,858
60 Added 2.05%
2,983 $238,000
Q4 2023

Jul 31, 2025

SELL
$57.42 - $83.61 $25,264 - $36,788
-440 Reduced 13.08%
2,923 $232,000
Q3 2023

Jul 31, 2025

BUY
$69.25 - $82.21 $1,315 - $1,561
19 Added 0.57%
3,363 $235,000
Q2 2023

Jul 31, 2025

BUY
$58.41 - $90.35 $38,725 - $59,902
663 Added 24.73%
3,344 $240,000
Q4 2022

Feb 06, 2023

SELL
$39.94 - $79.72 $132,001 - $263,474
-3,305 Reduced 55.21%
2,681 $206,000
Q3 2022

Nov 01, 2022

BUY
$36.06 - $69.85 $215,855 - $418,122
5,986 New
5,986 $267,000
Q1 2021

May 12, 2021

SELL
$55.91 - $81.44 $251,986 - $367,050
-4,507 Closed
0 $0
Q4 2020

Feb 16, 2021

BUY
$66.31 - $86.52 $298,859 - $389,945
4,507 New
4,507 $367,000

Others Institutions Holding AXSM

About Axsome Therapeutics, Inc.


  • Ticker AXSM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 42,878,000
  • Market Cap $5.99B
  • Description
  • Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinic...
More about AXSM
Track This Portfolio

Track Brinker Capital Investments, LLC Portfolio

Follow Brinker Capital Investments, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Brinker Capital Investments, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Brinker Capital Investments, LLC with notifications on news.